[breadcrumb_custom]

Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP)’s Stock Performance and Outlook

In the last trading session, 1.49 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.30. With the company’s per share price at $1.25 changed hands at $0.1 or 8.70% during last session, the market valuation stood at $283.66M. ADAP’s last price was a discount, traded about -48.0% off its 52-week high of $1.85. The share price had its 52-week low at $0.42, which suggests the last value was 66.4% up since then. When we look at Adaptimmune Therapeutics Plc ADR’s average trading volume, we note the 10-day average is 4.45 million shares, with the 3-month average coming to 1.16.

Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information

Instantly ADAP was in green as seen at the end of in last trading. With action 20.19%, the performance over the past five days has been green. The jump to weekly highs of 1.4198 added 8.70% to the stock’s daily price. The company’s shares are showing year-to-date upside of 57.63%, with the 5-day performance at 20.19% in the green. However, in the 30-day time frame, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) is 38.89% up. Looking at the short shares, we see there were 4.71 million shares sold at short interest cover period of 2.58 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts

Data shows that the Adaptimmune Therapeutics Plc ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 53.37% over the past 6 months, a 54.90% in annual growth rate that is considerably higher than the industry average of 15.50%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Adaptimmune Therapeutics Plc ADR will rise 44.40%, while the growth in revenue is estimated to hit -1,500.00% for the next quarter. Year-over-year growth is forecast to reach 196.70% up from the last financial year.

Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of $20.47 million. 5 analysts are of the opinion that Adaptimmune Therapeutics Plc ADR’s revenue for the quarter ending Mar 2024 will be $10.52 million. The company’s revenue for the corresponding quarters a year ago was $11.03 million and $47.6 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 85.60%. The estimates for the next quarter sales put growth at -77.90%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -5.40%. The 2024 estimates are for Adaptimmune Therapeutics Plc ADR earnings to decrease by -160.69%, but the outlook for the next 5-year period is at 1.00% per year.

ADAP Dividends

Adaptimmune Therapeutics Plc ADR is expected to release its next quarterly earnings report between March 04 and March 08.

On Key

Related Posts